
Ludovic Lhermitte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8377108/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. Blood Cancer Journal, 2022, 12, 14.	6.2	10
2	Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1356-1364.e2.	3.8	2
3	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. Modern Pathology, 2022, 35, 1227-1235.	5.5	5
4	Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype. Leukemia, 2021, 35, 764-776.	7.2	24
5	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia. Blood, 2021, 137, 1879-1894.	1.4	48
6	<i>IKZF1</i> alterations predict poor prognosis in adult and pediatric T-ALL. Blood, 2021, 137, 1690-1694.	1.4	8
7	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. Leukemia, 2021, 35, 724-736.	7.2	8
8	Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study. Modern Pathology, 2021, 34, 59-69.	5.5	15
9	Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia, 2021, 35, 2332-2345.	7.2	15
10	Adenylate kinase 2 expression and addiction in T-ALL. Blood Advances, 2021, 5, 700-710.	5.2	7
11	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. Journal of Hematology and Oncology, 2021, 14, 74.	17.0	10
12	The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis. Blood, 2021, 138, 2396-2407.	1.4	5
13	Epidemiology, clinical picture and longâ€ŧerm outcomes of <i>FIP1L1â€PDGFRA</i> â€positive myeloid neoplasm with eosinophilia: Data from 151 patients. American Journal of Hematology, 2020, 95, 1314-1323.	4.1	37
14	Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. Haematologica, 2020, 105, 1575-1581.	3.5	10
15	CBFÎ ² -SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia. Cell Reports, 2020, 30, 299-307.e3.	6.4	6
16	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia, 2020, 34, 1730-1740.	7.2	21
17	Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project. Blood, 2020, 136, 22-23.	1.4	2
18	Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 1008-1018.	1.5	18

LUDOVIC LHERMITTE

#	Article	IF	CITATIONS
19	Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2387-2395.e3.	3.8	42
20	<i>DNMT3A</i> mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. Haematologica, 2019, 104, 1617-1625.	3.5	40
21	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1981-1988.	5.2	12
22	The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL). Blood, 2019, 134, 1339-1339.	1.4	2
23	BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines. Blood, 2019, 134, 1683-1683.	1.4	3
24	A "foamy―mastocytosis case. Blood, 2018, 131, 586-586.	1.4	0
25	Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. Journal of Clinical Investigation, 2018, 128, 3071-3087.	8.2	133
26	Omalizumab: Efficacy and Safety in Mast Cell Disorders. Blood, 2018, 132, 4280-4280.	1.4	0
27	Longitudinal Evolution and Clinical Impact of Subclonal Mutational Architecture in Adult T Cell Leukemia/Lymphoma. Blood, 2018, 132, 2841-2841.	1.4	0
28	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet, The, 2017, 389, 612-620.	13.7	95
29	Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood, 2017, 129, 347-357.	1.4	323
30	Response to 5â€azacytidine in a patient with <i>TET2</i> â€mutated angioimmunoblastic Tâ€cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBVâ€positive large Bâ€cell lymphoma. Hematological Oncology, 2017, 35, 864-868.	1.7	33
31	Early Response–Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. Journal of Clinical Oncology, 2017, 35, 2683-2691.	1.6	134
32	An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Haematologica, 2016, 101, 732-740.	3.5	53
33	Genetically distinct leukemic stem cells in human CD34â^ acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. Journal of Experimental Medicine, 2016, 213, 1513-1535.	8.5	120
34	Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica, 2016, 101, 336-345.	3.5	50
35	Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. Immunity, 2016, 45, 610-625.	14.3	131
36	Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. Cancer Discovery, 2016, 6, 972-985.	9.4	33

LUDOVIC LHERMITTE

#	Article	IF	CITATIONS
37	Mastocytoses systémiques : aspects cytologiques et histologiques en hématologie. Revue Francophone Des Laboratoires, 2016, 2016, 31-41.	0.0	0
38	Targeting IRAK1 in T-Cell acute lymphoblastic leukemia. Oncotarget, 2015, 6, 18956-18965.	1.8	16
39	ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases. PLoS ONE, 2014, 9, e85362.	2.5	65
40	RUNX1-dependent RAG1 deposition instigates human TCR-ĺ´locus rearrangement. Journal of Experimental Medicine, 2014, 211, 1821-1832.	8.5	19
41	Toward a <i>NOTCH1/FBXW7/RAS/PTEN</i> –Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study. Journal of Clinical Oncology, 2013, 31, 4333-4342.	1.6	202
42	Mast cell leukemia. Blood, 2013, 121, 1285-1295.	1.4	153
43	Mast Cell Sarcoma: A Rare and Aggressive Entity—Report of Two Cases and Review of the Literature. Journal of Clinical Oncology, 2013, 31, e90-e97.	1.6	43
44	TLX Homeodomain Oncogenes Mediate T Cell Maturation Arrest in T-ALL via Interaction with ETS1 and Suppression of TCRα Gene Expression. Cancer Cell, 2012, 21, 563-576.	16.8	81
45	Eight Colors Flow Cytometry Phenotyping for Blood Minimal Residual Disease Monitoring in Hairy Cell Leukaemia Patients Blood, 2009, 114, 1609-1609.	1.4	1